Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.01
- Piotroski Score 2.00
- Grade N/A
- Symbol (OTIC)
- Company Otonomy, Inc.
- Price $0.08
- Changes Percentage (0%)
- Change $0.08
- Day Low $0.08
- Day High $0.08
- Year High $0.08
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 04/11/2023
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 07/24/2023
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.06
- Trailing P/E Ratio -0.14166666666667
- Forward P/E Ratio -0.14166666666667
- P/E Growth -0.14166666666667
- Net Income $-50,325,000
Income Statement
Quarterly
Annual
Latest News of OTIC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Matthew McConaughey shows patriotic pride at US Open alongside Taylor Swift, Bon Jovi
Matthew McConaughey celebrated a Texas Longhorns win at the US Open in patriotic style with an American flag bandanna. Celebrities like Taylor Swift, Travis Kelce, and Jon Bon Jovi were spotted enjoyi...
By Fox News | 1 day ago -
The Ferrari F430 Was Once a Middling Mid-Engine Exotic. Now Prices Are Rising Fast.
Despite a cooling collector car market, recent sales have defied this trend. Notably, a Ferrari and a Mercedes 280 SL sold for high prices due to unique qualities. Additionally, a manual transmission ...
By Yahoo! Finance | 3 days ago -
'Marpole rapist' granted full parole, victims' families concerned about lack of notice - BC | Globalnews.ca
Gary Jagur Singh, the "Marpole Rapist," has been granted full parole after rehabilitation efforts and evaluation, despite concerns about informing the public. Singh, convicted of sexually assaulting 1...
By Global News | 4 days ago
